Background
Pfizer developed amlodipine, a calcium channel blocker used to treat hypertension and angina, and commercialized it as Norvasc in the besylate salt form (amlodipine besylate). After obtaining FDA approval, Pfizer applied for and received a patent term extension under the Hatch-Waxman Act (35 U.S.C. § 156), which allows pharmaceutical companies to recover part of the patent term consumed by the lengthy FDA review process.
Pfizer’s underlying patent claimed amlodipine as a compound — including all of its salt forms — but the FDA had only approved amlodipine besylate specifically. Dr. Reddy’s Laboratories sought to market a generic drug using amlodipine maleate, a different salt of the same active ingredient. Dr. Reddy’s argued that the term extension only covered the specifically approved besylate salt, and therefore the maleate salt was outside the extension and free to be sold upon ANDA approval. The district court agreed with Pfizer; Dr. Reddy’s appealed.
The central question was how broadly the term “product” in 35 U.S.C. § 156 should be defined when the approved drug product is one salt form but the patent covers a broader chemical genus including all salt forms.
The Court’s Holding
The Federal Circuit affirmed the district court, ruling in Pfizer’s favor. Writing for the majority, Judge Newman held that § 156(f) expressly defines the term “product” to include “any salt or ester of the active ingredient.” Under this statutory definition, the patent term extension for amlodipine besylate extended to all salt and ester forms of amlodipine — including amlodipine maleate. The majority rejected Dr. Reddy’s narrow reading that would have limited the extension only to the specific chemical form approved by the FDA.
The court reasoned that Congress deliberately included the broad definition in § 156(f) to prevent the kind of “salt-switching” strategy Dr. Reddy’s was attempting: a generic company cannot avoid a term extension merely by substituting one pharmaceutically equivalent salt for another. To allow such a workaround would undermine the statutory purpose of the Hatch-Waxman extension, which was to compensate brand-name manufacturers for regulatory review time lost during FDA approval.
Chief Judge Mayer dissented, arguing that the extension should only cover the specific salt form actually reviewed by the FDA, because that was the product whose regulatory delay justified the extension.
Key Takeaways
- Under 35 U.S.C. § 156(f), a Hatch-Waxman patent term extension covers not just the specific FDA-approved salt, but any salt or ester of the same active ingredient covered by the patent.
- Generic manufacturers cannot circumvent a term extension by using a different salt or ester form of the same active pharmaceutical ingredient.
- The statutory definition of “product” in § 156(f) is broader than the specific FDA-approved formulation, encompassing the chemical genus.
- Brand-name drug companies receive meaningful protection against salt-form switching, preserving the value of their patent term extension rights.
- The dissent’s narrower view — that only the specifically approved salt should be covered — did not prevail but reflects ongoing tension in interpreting Hatch-Waxman’s scope.
Why It Matters
This ruling is significant for the pharmaceutical industry because it closes a potential loophole that generic manufacturers might otherwise exploit. If term extensions only covered the exact salt form the FDA reviewed, a generic company could slightly modify the molecular form of an active ingredient — swapping one counterion for another — and enter the market before the extension expired. The Federal Circuit’s broad reading of § 156(f) ensures that the economic rationale for term extensions — compensating for regulatory time loss — cannot be easily undermined.
For brand-name manufacturers, the decision reinforces that patent term extensions protect the active ingredient as a class, not merely a single chemical variant. For generic manufacturers, it means ANDA applicants must account for the full scope of a term extension before launching a product based on a different salt of a patented compound. The decision has been influential in subsequent pharmaceutical patent litigation involving Hatch-Waxman term extensions.